Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial

24 March 2023 (08:00 - 14:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Joakim Bo Kunkel

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

8 More presentations in this session

Presentation thumbnail

Haemoglobin drop in patients with myocardial infarction and without previous anaemia is associated with an increased incidence of heart failure and cardiogenic shock

Doctor M. Paralta De Figueiredo (Evora, PT)

Abstract Slides

Presentation thumbnail

Incidence rates of the different initial rhythms during out-of-hospital cardiopulmonary resuscitation and mortality of patients presenting ST elevation myocardial infarction

Doctor D. Szabo (Budapest, HU)

Abstract Slides

Presentation thumbnail

External validation of the ORBI risk score for cardiogenic shock prediction in patients with ST-segment elevation myocardial infarction

Doctor M. Riche (Toulouse, FR)

Abstract Slides

Presentation thumbnail

Adjusted pulse pressure associated with weaning from venoarterial extracorporeal membrane oxygenator in patients with acute myocardial infarction complicated by cardiogenic shock

Associate Professor J. Yang (Seoul, KR)

Abstract Slides

Presentation thumbnail

Therapeutic limitation in cardiogenic shock: lessons learnt from the Altshock-2 registry

Doctor V. Ditali (Brussels, BE)

Abstract Slides

Access the full session

Session thumbnail

Acute coronary syndromes, cardiogenic shock and acute kidney injury

The Event

Event poster

ESC Acute CardioVascular Care 2023

24 March - 26 March 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources